Projecting future drug expenditures - 1999

American Journal of Health-System Pharmacy

Volumn 56, Issue 1, 1999, Pages 31-39

  Mehl, Bernard ^a   Santell, John P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

Author keywords

Administration; Costs; Drugs; Economics; Food and Drug Administration (U.S.); Health care; Managed care systems; Pharmacy, institutional; Regulations

Indexed keywords

ALTEPLASE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BRINZOLAMIDE; CANDESARTAN HEXETIL; CAPECITABINE; CARDIOVASCULAR AGENT; CITALOPRAM; FOMIVIRSEN; GASTROINTESTINAL AGENT; GENERIC DRUG; HEMOSTATIC AGENT; HEPATITIS B VACCINE; LEFLUNOMIDE; LEPIRUDIN; LIPOTROPIC AGENT; NEUROTROPIC AGENT; PSYCHOTROPIC AGENT; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFAPENTINE; SILDENAFIL; SPASMOLYTIC AGENT; THALIDOMIDE; TIROFIBAN; TOLCAPONE; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG APPROVAL; DRUG COST; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HOSPITAL PHARMACY; MANAGED CARE; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0032901239     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.1.31     Document Type: Review

References (47)

1. Pharmaceutical Research and Manufacturers of America Facts & figures. http://www.phrma.org/facts (accessed 1998 Jan).
2. New drug approvals in 1997. Washington, DC: 1998 Jan.
3. Bullish new products and macro effects powering earnings flow. New York: Gruntal Investment Research; 1997 Jan 21:1.
4. Annual proprietary drug approval review. New York: Gruntal Investment Research; 1998 Mar 9.
5. x market, IMS says. FDC Rep. 1998; 60(Mar 9):9-10.
6. Winslow R. Health-care inflation kept in check last year. N Y Times. 1998; Jan 2:B-1.
7. Meyer H. The pills that ate your profit. Hosp Health Netw. 1998; (72(3):19-22.
8. Mehl B, Santell JP. Projecting future drug expenditures - 1998. Am J Health-Syst Pharm. 1998; 55:127-35.
9. Mehl B, Santell JP. Projecting future drug expenditures - 1997. Am J Health-Syst Pharm. 1997; 54:153-61.
10. Santell JP. Projecting future drug expenditures - 1996. Am J Health-Syst Pharm. 1996; 53:139-50.
11. Santell JP. Projecting future drug expenditures - 1995. Am J Health-Syst Pharm. 1995; 52:151-63.
12. Santell JP. Projecting future drug expenditures - 1994. Am J Hosp Pharm. 1994; 51:177-87.
13. Santell JP. Projecting future drug expenditures - 1993. Am J Hosp Pharm. 1993; 50:71-7.
14. Ensor PA. Projecting future drug expenditures - 1992. Am J Hosp Pharm. 1992; 49:140-5.
15. FDA drug approvals list. Washington, DC: 1996, 1997, 1998.
16. Thoroughly modern. R&D Directions. 1998; 4(2):60-1.
17. Pear R. Congress clears measure to speed drugs to market. N Y Times. 1997; Nov 10:A-28.
18. Economic section of the FDA modernization act of 1997 debated at ISPOR US legislation briefing. ISPOR News. 1998; 4(1):1.
19. Sharpe R. Some restrictions on drug makers' ability to promote off-label uses are overturned. Wall Str J. 1998; Jul 31:A-12.
20. Myshko D. The best pipelines. R&D Directions. 1997; 3(1): 16-45.
21. Myshko D. The best pipelines. R&D Directions. 1998; 4(1):24-47.
22. Saks DF. Bullish macro industry outlook. New York: Gruntal Investment Research; 1998 Jan 12:1.
23. Coming soon. R&D Directions. 1998; 4(3):26-7.
24. The generic industry. New York: Gruntal Investment Research; 1998 Feb 19:1.
25. Generic drug industry 1997. New York: Gruntal Investment Research; 1998 Jan 23:3.
26. Managed care will become greater force. Pharm Times. 1998; 64(2):37.
27. Generic price declines slow. Pharm Times. 1998; 64(3):37.
28. As some generics' prices soar, R.Ph's are crying foul. Drug Topics. 1989 142(5):23.
29. Generic pricing issue attracts attention of U.S. representatives. Wkly Pharm Rep. 1998; 47(Mar 23):3.
30. NAPM News Bull. 1998; Spring(32):2
31. Freudenheim M. Judge rejects two separate drug mergers. N Y Times. 1998 Aug 1:D-1,D-14.
32. Freudenheim M. Creating no. 1 drug wholesaler, Cardinal to buy Bergen Brunswig. N Y Times. 1997 Aug 26:D-1,D-2.
33. Freudenheim M. Two big drug wholesalers set a merger. N Y Times. 1997 Sep 24:D-1,D-2.
34. Marrow DJ. FTC votes to halt big drug mergers. N Y Times. 1998 Mar 4:D-1,D-3.
35. Brinkley J, Holson L. Aiding consumers is now the thrust of antitrust push. N Y Times. 1998 Mar 23:A-1,A-20.
36. Rankin K. FTC and wholesalers spar over mega-mergers. Pharm Times. 1998; 64:2 P18.
37. 4 Big drug wholesalers drop merger plans. N Y Times. 1998 Aug 8:D-3.
38. Fleming H Jr. Hey big spender! Drug Topics. 1998; 142(5):53.
39. Novartis pharmacy benefit report. Trends and forecasts. 1997.
40. Horn SD, Sharkey PD, Tracy DM et al. Intended and unintended consequences of HMO cost-containment strategies: results from managed care outcomes project. Am J Manag Care. 1996; 2:253-64.
41. Freudenheim M. Not quite what the doctor ordered. N Y Times. 1996 Oct 8:D-1,D-6.
42. Therapeutic switches resulting in adverse events. Wkly Pharm Rep. 1997; 46(Mar 10):2.
43. Wilson R. Health-care inflation kept in check last year. N Y Times. 1998 Jan 20:B-1.
44. Silverman ER. Switch to Merck drug brings landmark suit. Star-Ledger. 1998 Mar 20:1,19.
45. Freudenheim M. Health insurers seek big increases in their premiums. N Y Times. 1998 Apr 24:A-1,D-3.
46. Freudenheim M. Insurers tighten rules and reduce fees for doctors. N Y Times. 1998 Jun 10:A-1,A-18.
47. Weinstein MM. Fallen taboo: frank talk on Viagra is about cost. N Y Times. 1998 Jan 11:D1-D2.